Authors
Latest:
Dr Bhatnagar on Survival Outcomes With MRD Negativity in AMLBhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
Latest:
Empowering Breast Surgeons: A Call for Collective ActionAs survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
Latest:
Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS TreatmentLeading researchers in rare blood cancers to investigate new therapeutic strategy that targets leukemic stem cells.
Latest:
Dr Franco on the Integration of Immunotherapy Treatment in Endometrial CancerIdalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.
Latest:
Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian CancerJudy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.
Latest:
Future Directions for the Management of HR+ Breast CancerAndrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Latest:
Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPCAndrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian CancerAnil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple MyelomaSusan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.
Latest:
Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLCNicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.
Latest:
A Breakthrough for the “Lab Brat”Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AMLThe prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Latest:
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaThe study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).
Latest:
Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCLGeorg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.
Latest:
Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced MelanomaIván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.
Latest:
Biomarker Testing Standards-of-Care in Breast and Lung CancerThe panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.
Latest:
Future Perspectives in the Treatment of NeuroblastomaGiselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.
Latest:
Optimizing the Treatment of CLL With Novel TherapiesOncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Latest:
Dr. Funchain on the Rationale for the SWOG S1404 Trial in MelanomaPauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.
Latest:
Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid TumorsStéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.
Latest:
Dr Rutkowski on the Safety Profile of Avelumab Plus Axitinib in GISTPiotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST
Latest:
Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA MutationsKara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.
Latest:
Dr Roof on Disparities in Lung Cancer Mortality Rates in the United StatesLogan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.
Latest:
Dr. Jamieson on Treatment Considerations in MyelofibrosisCatriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.
Latest:
Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCLScott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr Habermann on Ongoing Trials in MCL and MZLThomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.
